Abstract Akt/PKB serine/threonine kinase is a leading signalling modulator for several cellular processes including metabolism, growth, proliferation and survival. However, complexity and diversity in the upstream/downstream arms of Akt pathway, as recent genetic studies reported, challenge considerably the evolvement of effective targeted therapies. The aim was to study the expression of phosphoAkt1 (pAkt) in breast cancer (BC), with respect to different component proteins upstream/downstream of Akt pathway activation, clinicopathologic parameters and patients' outcome. pAkt (Ser473) was evaluated by immunohistochemistry, on tissue microarrays containing 1,202 early invasive BC with long-term clinical follow-up. Seventy-six percent of the studied tumours overexpressed pAkt, where it was associated with expression of oestrogen and androgen receptors, PIK3CA, cytokeratin (CK)18, CK19 and PTEN. Loss of pAkt was correlated with high grade, CK5/6, p53 and high Ki67 labelling index. Higher proportions of luminal tumours were pAkt positive relative to triple negative/basal subtypes. However, pAkt overexpression was not associated with breast cancer specific (BCSS) or metastasis-free survival (MFS). Four tumour phenotypes were identified based on PIK3CA and pAkt expression, with substantial proportions being PIK3CA -/pAkt ? or PIK3CA
receptors having intrinsic tyrosine-kinase activity. Such binding phosphorylates (activates) the intracellular tyrosine-kinase-containing moiety of the receptor [6] . One of the several proteins recruited and activated by the tyrosine phosphorylated growth factor receptor is PI3-kinase, which converts phosphatidyl inositol-4,5-bisphosphate (PIP2) at the 3 0 position of the inositol ring to PIP3, leading to recruitment of Akt1 via its pleckstrin homology (PH) domain to the plasma membrane. Akt1 phosphorylation is mediated by phosphatidyl inositol-3-phosphate-dependent kinase, PDK1, which phosphorylates Akt1 at Threonine (Thr) 308, and another kinase that phosphorylates it at Serine (Ser) 473 [7] [8] [9] . In addition, other Akt1 activators have been reported including DNA-PK, oxidative stresses, HSP90 (heat shock protein-90KDa), PKC-b (protein kinase C-Beta), integrins via focal adhesion kinase (FAK), and others [10, 11] .
Phosphorylated Akt, pAkt, exerts its effects in the cell by phosphorylating a wide variety of downstream substrates including caspase 9, MDM2, androgen receptor (AR), p21, p27, GSK (glycogen synthase kinase), and others [12] . These alterations culminate in pleiotropic biological events, including cell growth, survival and migration, which contribute not only to oncogenesis but also to tumour progression [1, 2] .
Constitutive activation of Akt1 occurs in human cancer through different mechanisms. Firstly, deletion and mutation of PTEN (phosphatase and tensin homolog), the phosphatase that dephosphorylates PI3-K and hence negatively regulating Akt [13] . Secondly, through amplification of the Akt gene [14] , or PH domain mutation of Akt1 leading to increased its affinity for phosphoinositides and membrane localisation [15] , and thirdly through amplification or mutation of the PIK3CA [16] .
Currently, an abundance of basic and pre-clinical studies have been conducted to elucidate implications of pAkt pathway derangements in breast cancer using different detection systems and tissue platforms [17, 18] . The use of immunohistochemistry (IHC) has been collectively considered as a useful means of identifying the Akt status in a wide range of human cancers including BC with most studies reporting that increased pAKT expression correlates with clinical aggressiveness and progression [19, 20] , while others find no such associations [21] . However, the complexity and diversity in the upstream and downstream arms of this pathway, reinforced by recent genetic studies [22, 23] , bear considerable challenges and limitations that might confront the clinical evolvement of effective targeted therapies [5] .
This study was conducted to determine the pAkt status in a large series of human invasive breast cancer to study the relationship of its expression with different upstream/ downstream component proteins, as well as correlations with clinicopathological parameters and disease outcome. This retrospective study adheres to REMARK criteria [24] .
Materials and methods

Patients and tumours
This study was conducted on a well-characterised series of early stage (pT1 and pT2) primary operable invasive breast carcinoma from patients enrolled into the Nottingham Tenovus Primary Breast Carcinoma Series that presented at Nottingham City Hospital between 1990 and 1998. Patients were under the age of 70 years and managed in a uniform manner. Patients' clinical history and tumour criteria, information on therapy and outcomes were available and prospectively maintained. Outcome data included survival status (whether alive, or deceased), survival time (in months), cause of death (died from breast cancer, other cause, or lost to follow-up), disease-free interval (DFI), time to loco-regional recurrence, and/or distant metastasis. The Breast Cancer Specific Survival (BCSS) is defined as the time (in months) from the date of primary surgery to the date of breast-cancer-related death. DFI is defined as the duration (in months) from the date of primary surgery to the appearance of loco-regional recurrence or distant metastasis. Data on a wide range of biomarkers of known clinical and biological relevance to breast cancer were available [25] . These include, hormone receptors [oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR)], epidermal growth factor receptor family members [HER1 (EGFR), HER2, HER3 and HER4], cytokeratins (CKs); basal CKs (CK5/6 and CK14), and luminal CKs (CK18 and CK19), tumour suppressor genes (p53 and PTEN), the Akt pathway activator PIK3CA, proliferation-related and cell cycle regulator markers (Ki-67, p21, p27, Bcl2 and cyclin D1), and cadherin family members (E-cadherin and P-cadherin) [25, 26] .
The patients had a median age at diagnosis of 54 years (range 18-70 years) with a median overall survival of 125 months (range 4-243 months) and the median time of event-free survival of 112 months (range 2-239 months). Distant recurrence occurred in 375 cases (31%), while 313 (26%) patients died from breast cancer, and 689 (59%) patients were alive at the end of follow-up.
This study was approved by Nottingham Research Ethics Committee 2 under the title of ''Development of a molecular genetics classification of breast cancer''.
Immunohistochemistry
Expression of pAkt1 in breast cancer was assessed using immunohistochemistry. Four micrometre sections were cut from paraffin processed block of previously prepared tissue microarrays (TMAs) and mounted on Superfrost slides (Surigpath). Sections were deparaffinised and heat-induced retrieval of antigen epitope was performed in citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 10 min. The sections were incubated at room temperature for 60 min with polyclonal antibody against S473pAkt1 (RB-10369-P1, Neomarkers, Fremont, CA, USA) optimally diluted 1:150, Following wash in TBS, sections were for 60 min in Strept AB complex (Dako, Denmark) diluted in 1:100 in normal swine serum/TBS, followed by chromagen for visualisation 0 Diaminobenzidine tetrahydrochloride (Dako liquid DAB Plus, K3468; Dako, Denmark)]. Sections were counterstained with Mayer's haematoxylin. Negative (primary antibody replaced by TBS) and positive (a known pAkt positive full-face BC tissue section) controls were included in the staining run.
Validation of anti-phospho-Akt (S473) antibody specificity For validation of anti-phospho-Akt (S473) antibody specificity, Western blotting was performed on whole cell lysates of MCF-7 and MDA-MB231 human breast cancer cell lines (obtained from the American Type Culture Collection; Rockville, MD, USA) using 1:100 dilution of the primary antibody dilution, and 1:2,000 of the HRP labelled secondary anti-rabbit antibody. BSA was used for blocking. ECL was used to visualise the membrane as previously described [27] .
TMA IHC scoring
Stained TMAs sections were scored using the semi-quantitative H score (Histochemical score) visual approach, taking into consideration the intensity of staining and the percentage of stained cells [28] within each tissue core. Staining intensity was scored as 0, 1, 2 or 3 for negative, weak, moderate and strong, respectively. The proportion (percentage) of positive cells for each intensity was subjectively estimated. Final scores were obtained by the sum of multiplying each staining intensity by its proportion, producing an H score ranging from 0 to 300. All cases were scored without prior knowledge of the patients' pathologic or outcome data.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, USA). Cut-off values for the different biomarkers included in this study were chosen before statistical analysis. Standard cut-offs were used for established prognostic factors and were the same as for previously published patient series [25, 26] . Determination of the optimal pAkt cut-offs for pAkt staining was obtained using pAkt H score frequency distribution histogram. Analysis of categorical variables was performed using the appropriate statistical test. Survival estimates were analysed by Kaplan-Meier method with significance determined by the Log Rank test. Multivariate analysis was performed by Cox proportional hazard analysis. A p value \0.05 (two-sided) was considered significant.
Results
The pAkt expression in stained TMA sections (n = 1,202) showed homogenous cytoplasmic immunoreactivity in invasive tumour cells (Fig. 1a, b) . The specificity of the antibody was confirmed using a Western blotting analysis of MCF-7 and MDA-MB231 human breast cancer cell lines, which showed a specific band at the correct predicted size (*60 kDa) of the pAkt protein confirming the specificity of the antibody used in the IHC staining (Fig. 1c ). The distribution of pAkt H score did not display normal distribution (median = 100). Using the pAkt H score frequency distribution histogram, the optimal cut-off point for pAkt positivity was set at 65 (taken at the mid-point of the observed trough in the distribution histogram of pAkt), that dichotomised the cohort into two categories: pAkt negative (H score \65), and pAkt positive expression (H score C65). Therefore, 914/1202 (76%) cases were positively stained with pAkt, with the remaining cases 288 (24%) were negative.
Association of pAkt with clinicopathologic parameters Correlation between pAkt expression and the expression of other biomarkers and molecular classes of breast cancer A significant positive association was found between pAkt and expression of ER, androgen receptor (AR), luminal CKs, HER4, PIK3CA and PTEN. In addition, loss of pAKT expression was associated with p53 positive, basal CKs positive, and tumour growth fraction as assessed by the Ki-67/MIBLI. However, no associations were found between pAkt and the expression of PR, the adhesion molecules E-cadherin and p-cadherin, or with the cell cycle regulators p21, p27, and Bcl-2.
The correlation between pAkt status and expression of the HER family members was investigated. Although there was a positive association between pAkt expression and the expression of HER4, no associations were found between pAkt and the expression of EGFR, HER2 or HER3. Tumours were profiled based on their HER family members expression into three groups; (a) HER2
-/HER1,3&4 Table 2 ).
Association of pAkt with patients' outcome
Although univariate survival analyses showed that there was no significant difference between patients with pAkt positive and negative tumours for BCSS and metastasisfree survival, MFS, (log rank, (LR) = 2.643, p = 0.104, and LR = 2.265, p = 0.132, respectively), patients with pAkt positive tumours showed a trend towards a relatively shorter BCSS and MFS when compared to those showing pAkt negativity (Fig. 2a, b) .
PIK3CA/pAkt combinatorial groups
To address interactions between pAkt and PIK3CA expression and its correlation with clinicopathological parameters and patients' outcomes, tumours were redefined based on their expression of both pAkt and PIK3CA, resulting in four phenotypic groups; PIK3CA -/pAkt -, PIK3CA
-/pAkt ? , PIK3CA ? /pAkt -, and PIK3CA ? /pAkt ? . Table 3 displays the resulting numbers and percentages of this combination. The majority of tumours showed PIK3CA
? /pAkt -phenotype while PIK3CA -/pAkt ? was the least common phenotype.
Significant positive association was found between these phenotypic groups and patient age (p = 0.001), menopausal status (p = 0.001), tumour grade (p \ 0.001), LVI (p \ 0.001), NPI (p \ 0.001), and molecular subtype (p \ 0.001). Importantly, PIK3CA
? groups showed more aggressive features regardless of the expression of pAkt (PIK3CA ? /pAkt -and PIK3CA ? /pAkt ? ). These groups showed association with higher histological grade, LVI positivity and were in the moderate and poor NPI categories (p [ 0.05).
Using the Kaplan-Meier survival plots and log rank statistics, significant differences were noticed between these phenotypes for patients' BCSS and MFS, (LR = 15. ? /pAkt -and PIK3CA ? /pAkt ? tumours. 
Discussion
The expression of pAkt in this study, as determined by IHC, demonstrated that 914/1202 (76%) of investigated tumours overexpressed pAkt. This relatively high prevalence of pAkt may be reflection of its oncogenetic role that was reported to occur early during the cascade of carcinogenic events, seen in the in situ stage carcinomas prior to their progression to invasive carcinomas [29] . A significant inverse association was found between pAkt and tumour grade, with a trend toward significance with individual grade components especially mitosis, which is reinforced by the significant negative association with proliferative fraction as assessed by MIB1-LI and are in accordance with previous studies [30] . However, other investigators reported direct association of pAkt with tumour grade [31, 32] . In line with others [33] , a direct association was revealed between pAkt expression and patients' age and menopausal status. Moreover, histologic tumour types of favourable outcome (invasive tubular, lobular, and invasive papillary carcinomas) displayed high proportions of pAkt overexpression, relative to medullary carcinomas; a type with relatively less favourable prognosis; which is inverse to the expression of PIK3CA in the same cohort [34] .
Importantly, pAkt expression was positively associated with ER status, a further demonstration of previous reports of Akt activation downstream of ER [35] . However, of the HER family (EGFR, HER2, HER3 and HER4), which are well-known Akt upstream activators, only HER4 showed positive association with pAkt, while no associations were found with EGFR, HER2 status, or HER3. The cooperation between the HER receptors with HER2 to produce a more aggressive tumour phenotype is well-evidenced [36] . Therefore, we profiled our tumour series based on their HER2 status with respect to the other HER family members. Interestingly, no association was found between the resulting subgroups and the pAkt status. These findings may point to other mechanisms of constitutive Akt activation, other than growth factor stimulation via receptor tyrosine kinase [14] [15] [16] . In line with this hypothesis is the significant positive association between pAkt and PTEN expression, which was available in only a subset of tumours of this series, despite the expected and reported inverse relationship between the two [37] . In addition, pAkt overexpression was directly correlated to the expression of AR, a known downstream pAkt target.
Lin et al. [38] demonstrated that AR phosphorylation via pAkt abrogates AR-induced apoptosis resulting in increased cell survival. On the other hand, pAkt was inversely associated with the IHC expression of p53 in our series, where p53 negative/wild cases showed higher proportions of pAkt positivity than p53 positive cases. However, this could not solely be explained through the action of pAkt on the p53 degradation mediator Mdm2, which showed no correlation with pAkt expression. In this respect, growing evidence challenge the conventional simplistic view that proposes Mdm2 as the principal mediator for p53 turnover, where many other factors are integral members of the multi-faceted p53 pathway [39] .
Of utmost interest is the correlation seen between pAkt expression and the BC molecular subtypes, where the luminal-like subtype displayed a higher frequency of pAkt positivity than the basal-like and TN subtypes. This association might mirror the positive association between pAkt with ER, luminal CK18, 19 and the negative association with basal CK14 found in our series; and on the other hand supports other reports attributing the resistance to adjuvant hormonal therapy to the activation of Akt in hormone receptor positive cases [40] . Despite the strong correlation with histologic grade, hormonal receptor status and BC molecular subtypes, the association of pAkt expression with patients' BCSS or MFS during the period of follow-up did not reach statistical significance. These findings might not be surprising, firstly because of the dependency of pAkt status in our series on ER expression whose its prognostic significance is reported to be dependent on age, lymph node status and length of follow-up time [41] . Secondly, it may be due to the high proportion of tumours showing pAkt expression implying an early activation of Akt pathway in these cases, rather than a feature of tumour progression [29] .
For further scrutiny of the results of pAkt expression in our series relevant to the upstream Akt activator PI3K, tumours were redefined according to their combined pAkt and PIK3CA IHC status, resulting in four phenotypic groups; PIK3CA -/pAkt -(double negative), PIK3CA -/ pAkt ? , PIK3CA ? /pAkt -, and PIK3CA ? /pAkt ? (double positive). Significant differences were noticed between these combinatorial phenotypic groups for patients' BCSS and MFS, independently of other prognostic parameters except grade; a similar pattern to that previously reported for PIK3CA expression in this cohort [34] . Interestingly, a substantial proportion (*16%) of tumours was PIK3CA -/ pAkt ? , meaning that the Akt was activated whereas the main upstream PI3K activator was inactive. The activation of Akt in this subset of tumours may be an indication of other mechanisms of Akt activation other than PI3K [13] [14] [15] . In addition, a comparable subset of tumours was PIK3CA
? /pAkt -, indicating diminished pAkt levels in the presence of PI3K over-activity. A growing body of evidence has recently reported a diminished Akt activation in breast tumours and cell lines harbouring the activating PIK3CA mutations, denoting an Akt-independent execution of downstream oncogenic signals of PI3K [22, 23] . Furthermore, the largest subset of tumours was the double positive tumours (*60%), in which both PI3K/Akt was active. In this subset, the activation of Akt is most probably a downstream effect of PI3K activation, although other Akt activators might also have contributed. This phenotype displayed a 10-year BCSS and MFS of 72 and 68% respectively, nearly equal to these displayed by the PK3CA
? /pAkt -phenotype. In other terms, the outcome of patients relative to pAkt status has been mostly driven by PIK3CA status, thus when the latter was positive, the prognosis was more or less the same to that of PIK3CA
? / pAkt -phenotype, but was dramatically poorer than PIK3CA -/pAkt ? tumours. It is noteworthy that the PIK3/Akt pathway inhibitors, as specific cancer therapies, are currently in their early phase of clinical trials [5] . In addition, current research strategies to limit PI3K/Akt signalling focus primarily on inhibitors of the PI3K catalytic subunit, which would not be as effective in cases of constitutively active Akt [22, 42] . With the findings of the current study in mind, specific inhibitors that target Akt should be considered within the specific context of Akt activation whether it is a result of an upstream stimulation, genetic mutation or gene amplification [13] [14] [15] . For instance, the prevalence and importance of Akt pathway activation with or without PI3K activation, represented in our series by the double positive and PIK3CA -/pAkt ? phenotypes respectively, might warrant the clinical effectiveness of specific Akt inhibitors. However, the pervasiveness of Akt-independent effectors of PI3K signalling, represented in our series by the PIK3CA
? / pAkt -phenotype, might therefore substantially limit the clinical effectiveness of Akt inhibitors in this subset of tumours.
Therefore, to develop effective new cancer therapeutics that could limit constitutively active Akt signals, it will be important to gain a more complete insight of the precise upstream and downstream members of this complex kinase pathway, and the specific PI3K/Akt axis in particular, in more specific rather than general signalling terms.
